Visit Abzena at booth #712 during PEGs Boston on May 13-17, 2024!
As a leader in ADC development, we offer bespoke services from antibody engineering to conjugation and payload delivery. Our deep expertise in bioconjugation technology enables us to create targeted therapies. By prioritizing safety and efficacy, we ensure that our ADC solutions meet the highest standards.
Our team of Greg Downs, VP of Development, Stephen Grant, VP of Development, Rob Holgate, VP, Research and Innovation and Jeff Mocny, Scientific Leader, will be on hand to discuss how we can support your needs.
Don’t miss our presentation on Thursday, May 16, 2024, from 10:20 – 10:35 AM on the Oncology Stream stage:
ThioBridge® – A Tool for the Design, Optimization & Manufacture of ADCs
ThioBridge® is a next-generation linker technology that makes use of the naturally occurring interchain disulfide bonds of an antibody to generate antibody-drug conjugates (ADCs). The ThioBridge® platform has several key features including homogeneity (with high conversion to a single DAR species), stability (as the linker does not deconjugate or cross-conjugate), site-specificity (due to conserved locations of conjugation), and flexibility (with different architectures allowing to access single DAR 2, 4 and 8 conjugates). The ThioBridge® platform is also compatible with a variety of cytotoxic payloads and can incorporate novel linker architecture, allowing the development of ADCs across a broad range of antibody and drug combinations, resulting in improved solubility, conjugation and efficacy in animal models.
Speaker: Rob Holgate, VP, Research and Innovation
Set an appointment today!
Event Information:
May 13-17, 2024
Omni Boston Hotel at the Seaport, Boston, MA
